For instance, studies demonstrated reduced tumor burden in mice using CD19-specific CAR-T cells in leukemia model.625,626 Furthermore, recent research by Pablo et al. showcased the efficacy of allogeneic CD123 CAR-Delta One T (DOT, Vδ1+) cells, which target the interleukin-3α chain receptor (CD123) expressed on acute myeloid leukemia (AML) blasts, in the treatment of AML in mice.627 Additionally, allogeneic CD20-targeted CAR Vδ1+ γδ T cells, specifically designed to target the B-cell-restricted CD20 antigen, exhibited anti-tumor activity in a B-cell lymphoma mouse model. This evidence concerns the gene CD19 and acute myeloid leukemia.